Market Research Logo

Friedreich Ataxia Global Clinical Trials Review, H2, 2017

Friedreich Ataxia Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, “Friedreich Ataxia Global Clinical Trials Review, H2, 2017 provides an overview of Friedreich Ataxia clinical trials scenario. This report provides top line data relating to the clinical trials on Friedreich Ataxia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Table Figure 1: Friedreich Ataxia Therapeutics, Global, Clinical Trials by Region (%), 2017*
    • Table Friedreich Ataxia Therapeutics, Global, Clinical Trials by Region, 2017*
    • Clinical Trials and Average Enrollment by Country
      • Table Figure 2: Friedreich Ataxia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
      • Table Friedreich Ataxia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
      • Table Figure 3: Friedreich Ataxia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
      • Table Friedreich Ataxia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
        • Table Friedreich Ataxia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017*
      • Top Five Countries Contributing to Clinical Trials in Europe
        • Table Figure 4: Friedreich Ataxia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
        • Table Friedreich Ataxia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
      • Top Countries Contributing to Clinical Trials in North America
        • Table Figure 5: Friedreich Ataxia Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
        • Table Friedreich Ataxia Therapeutics Clinical Trials, North America, Top Countries, 2017*
  • Clinical Trials by G7 Countries: Proportion of Friedreich Ataxia to Central Nervous System Clinical Trials
    • Table Figure 6: Proportion of Friedreich Ataxia to Central Nervous System Clinical Trials, G7 Countries (%), 2017*
    • Table Proportion of Friedreich Ataxia to Central Nervous System Clinical Trials, G7 Countries (%), 2017*
  • Clinical Trials by Phase in G7 Countries
    • Table Figure 7: Friedreich Ataxia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
    • Table Friedreich Ataxia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Clinical Trials in G7 Countries by Trial Status
    • Table Figure 8: Friedreich Ataxia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
    • Table Friedreich Ataxia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Clinical Trials by Phase
    • Table Figure 9: Friedreich Ataxia Therapeutics, Global, Clinical Trials by Phase (%), 2017*
    • Table Friedreich Ataxia Therapeutics, Global, Clinical Trials by Phase, 2017*
    • In Progress Trials by Phase
      • Table Figure 10: Friedreich Ataxia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
      • Table Friedreich Ataxia Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
  • Clinical Trials by Trial Status
    • Table Figure 11: Friedreich Ataxia Therapeutics, Global, Clinical Trials by Trial Status, 2017*
    • Table Friedreich Ataxia Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Clinical Trials by End Point Status
    • Table Figure 12: Friedreich Ataxia Therapeutics Clinical Trials, Global, by End Point Status, 2017*
    • Table Friedreich Ataxia Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Subjects Recruited Over a Period of Time
    • Table Figure 13: Friedreich Ataxia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
    • Table Friedreich Ataxia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Clinical Trials by Sponsor Type
    • Table Figure 14: Friedreich Ataxia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
    • Table Friedreich Ataxia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
  • Prominent Sponsors
    • Table Figure 15: Friedreich Ataxia Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
    • Table Friedreich Ataxia Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
    • Top Companies Participating in Friedreich Ataxia Therapeutics Clinical Trials
      • Table Figure 16: Friedreich Ataxia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
      • Table Friedreich Ataxia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Prominent Drugs
    • Table Figure 17: Friedreich Ataxia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
    • Table Friedreich Ataxia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
  • Latest Clinical Trials News on Friedreich Ataxia
    • Aug 14, 2017: FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich's Ataxia
    • Jun 01, 2017: Reata Pharmaceuticals Announces Positive Data From Part One of Moxie Trial of Omaveloxolone for Friedreich's Ataxia
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table Figure 18: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report